title: Serum midkine as a predictor of cardiac events in patients with chronic heart failure.
abstract: BACKGROUND
  Midkine, a heparin-binding growth factor, has various functions such as migration of inflammatory cell and anti-apoptotic effect. Invasion of inflammatory cell and cardiomyocyte apoptosis are involved in development and progression of heart failure (HF). However, the relationship between midkine and HF has not been previously examined. Therefore, we examined clinical significance of serum midkine levels to determine the prognosis of HF patients.
  
  
  RESULTS
  Serum levels of midkine were measured at admission in 216 consecutive patients hospitalized for HF and 60 control subjects. Patients were prospectively followed during a mean follow-up period of 653 +/- 375 days with the end points of cardiac death and progressive HF requiring rehospitalization. Serum concentrations of midkine were significantly higher in patients with HF than in controls. Patients with cardiac events had significantly higher concentrations of midkine than those without cardiac events. Kaplan-Meier analysis revealed that cardiac event rates increased markedly as midkine levels rose. Furthermore in the multivariate analysis, after adjustment for age, gender ,and complications, midkine was the independent predictor of cardiac events.
  
  
  CONCLUSIONS
  Serum midkine levels are increased in HF patients, and midkine is a novel marker for risk stratifying HF patients.
authors.affiliation: Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Kitahara
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Shishido
authors.forename: Satoshi
authors.initials: S
authors.lastname: Suzuki
authors.forename: Shigehiko
authors.initials: S
authors.lastname: Katoh
authors.forename: Toshiki
authors.initials: T
authors.lastname: Sasaki
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Ishino
authors.forename: Joji
authors.initials: J
authors.lastname: Nitobe
authors.forename: Takuya
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Takehiko
authors.initials: T
authors.lastname: Miyashita
authors.forename: Tetsu
authors.initials: T
authors.lastname: Watanabe
authors.forename: Yasuchika
authors.initials: Y
authors.lastname: Takeishi
authors.forename: Isao
authors.initials: I
authors.lastname: Kubota
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000401:mortality / Q000503:physiopathology; D002908:Chronic Disease; D016207:Cytokines / Q000097:blood*; D003971:Diastole / Q000502:physiology; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000401:mortality / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078792:Midkine; D011237:Predictive Value of Tests; D011446:Prospective Studies; D015203:Reproducibility of Results; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends; D013599:Systole / Q000502:physiology; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000401:mortality / Q000503:physiopathology
chemical_list: D015415:Biomarkers; D016207:Cytokines; D000078792:Midkine